On October 24, 2025, Genenta Science (NASDAQ: GNTA) and Anemocyte announced a new strategic collaboration to expand the production of off‑the‑shelf lentiviral vector (LVV) plasmid DNA. The partnership builds on the existing relationship that began in May 2025 and focuses on delivering high‑quality plasmid DNA from research and development stages through GMP‑grade manufacturing for clinical and commercial use.
The collaboration leverages Genenta’s proprietary LVV plasmid DNA technology, originally developed from the foundational research of Professor Luigi Naldini, co‑founder of Genenta. By making this platform available to Anemocyte, the partnership enables the BMO to provide a reliable source of top‑quality materials for advanced therapy programs, covering the entire spectrum from preclinical to commercial stages.
CEO Pierluigi Paracchi said, “Our expanded collaboration with ANEMOCYTE represents a natural progression of a successful partnership in plasmid DNA manufacturing. By making our clinically validated LVV Plasmid DNA technology platform available to ANEMOCYTE and its clients, we are contributing to the reliable and scalable development of advanced therapy programs across the industry.” Anemocyte CEO Marco Ferrari added, “Our collaboration with Genenta has already yielded excellent results. By formalizing this new partnership, we are ensuring our clients have access to a robust, well‑established platform for their advanced therapy programs, backed by Genenta’s extensive track record.”
For Genenta, the expanded partnership strengthens its manufacturing capabilities and reduces dependence on external suppliers for critical starting materials. The ability to produce off‑the‑shelf LVV plasmid DNA in-house or through a trusted partner supports the scaling of Temferon’s clinical pipeline and may accelerate timelines for future trials. The move also signals to investors that Genenta is proactively addressing supply‑chain challenges, potentially improving the feasibility of bringing its lead product to market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.